Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Hospital-based RNA Therapeutics

Version 1 : Received: 22 December 2021 / Approved: 6 January 2022 / Online: 6 January 2022 (11:20:59 CET)

How to cite: Damase, T.; Sukhovershin, R.; Zhang, M.; Kiss, D.; Cooke, J. Hospital-based RNA Therapeutics. Preprints 2022, 2022010073 (doi: 10.20944/preprints202201.0073.v1). Damase, T.; Sukhovershin, R.; Zhang, M.; Kiss, D.; Cooke, J. Hospital-based RNA Therapeutics. Preprints 2022, 2022010073 (doi: 10.20944/preprints202201.0073.v1).

Abstract

Hospital-based programs democratize mRNA therapeutics by facilitating the processes to translate a novel RNA idea from the bench to the clinic. Because mRNA is essentially biological software, therapeutic RNA constructs can be rapidly developed. The generation of small batches of clinical grade mRNA to support IND applications and first-in-man clinical trials, as well as personalized mRNA therapeutics delivered at the point-of-care, is feasible at a modest scale of cGMP manufacturing. Advances in mRNA manufacturing science and innovations in mRNA biology, are increasing the scope of mRNA clinical applications.

Keywords

Messenger RNA • Hospital-based mRNA therapeutics • circular mRNA • self-amplifying mRNA • RNA-based CAR T-cell • RNA-based gene-editing tools

Subject

MEDICINE & PHARMACOLOGY, Other

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.